- US-listed companies
- Moleculin Biotech, Inc.
Moleculin Biotech, Inc.MBRX
Market cap
$73.33M
P/E ratio
Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | |
Net loss | -3,926,361 | -10 | -12 | -13 | -17 | -16 | -29 |
Depreciation and amortization | 6,162 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation | 323,974 | 1 | 1 | 2 | 2 | 2 | 2 |
Change in fair value of warrant liability | - | 3 | -3 | -4 | -2 | -7 | -1 |
Operating lease, net | - | - | - | - | - | 0 | 0 |
Prepaid expenses and other current assets | 215,052 | 0 | 0 | 2 | -1 | -0 | 1 |
Accounts payable | - | 0 | 0 | 1 | -1 | 0 | 1 |
us-gaap_IncreaseDecreaseInAccruedLiabilities | - | 0 | 1 | -1 | 0 | 0 | 0 |
Net cash used in operating activities | - | -7 | -12 | -17 | -18 | -19 | -28 |
Purchase of fixed assets | 21,470 | 0 | 0 | 0 | 0 | 0 | 0 |
Net cash used in investing activities | - | -0 | -0 | -0 | -0 | -0 | -0 |
Proceeds from exercise of warrants | - | 4 | 0 | 2 | 0 | 0 | - |
Payment of tax liability for vested restricted stock units | - | - | - | - | 0 | 0 | 0 |
Proceeds from sale of common stock, net of issuance costs | - | - | - | - | 23 | 75 | - |
Net cash provided by (used in) financing activities | - | 10 | 12 | 21 | 23 | 75 | -0 |
Effect of exchange rate changes on cash and cash equivalents | - | - | - | -0 | 0 | -0 | -0 |
Net change in cash and cash equivalents | - | - | - | 4 | 4 | 56 | -28 |